2020
323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
Pusztai L, Lu H, Hale C, Grosse-Wilde A, Specht J, Modi S, Han H, Cortes J, Oliveira M, Garfin P, Wang Z, Onsum M. 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients. 2020, a198-a199. DOI: 10.1136/jitc-2020-sitc2020.0323.Peer-Reviewed Original Research
2015
Chemotherapy and the recurrence score—results as expected?
Pusztai L. Chemotherapy and the recurrence score—results as expected? Nature Reviews Clinical Oncology 2015, 12: 690-692. PMID: 26552957, DOI: 10.1038/nrclinonc.2015.191.Peer-Reviewed Original Research